Veilleux M, Lette J, Mansur A, Bertrand C, Cerino M, Picard M, McNamara D, Eybalin M C, Levasseur A, Nattel S
Maisonneuve-Rosemont Hospital, Montreal Heart Institute, Quebec.
Can J Cardiol. 1994 Mar;10(2):259-62.
To determine the prognostic implication of exercise and dipyridamole-induced transient left ventricular cavitary dilation (TLVD).
TLVD was observed and a follow-up obtained in 61 patients after exercise and in 62 patients following dipyridamole infusion.
There was no statistical difference between groups in terms of sex, history of hypertension, diabetes, renal failure, previous myocardial infarction, severity of angina syndrome, congestive heart failure, resting electrocardiographic (ECG) abnormalities, clinical or ECG signs of ischemia during stress, number of reversible perfusion defects on thallium images or duration of follow-up (21 months).
Dipyridamole patients were slightly older (64 versus 57 years) and displayed more thallium redistribution (P = 0.002). After a mean follow-up of 21 months, both fatal and nonfatal (myocardial infarction or cardiac death) cardiac events were more frequent in the dipyridamole group (50% versus 9%, P = 0.0001).
Patients with dipyridamole-induced TLVD are at greater risk than those with exercise-induced TLVD at the authors' institution.
确定运动和双嘧达莫诱发的短暂性左心室腔扩张（TLVD）的预后意义。
观察了61例运动后患者和62例输注双嘧达莫后的患者的TLVD情况并进行随访。
两组在性别、高血压病史、糖尿病、肾衰竭、既往心肌梗死、心绞痛综合征严重程度、充血性心力衰竭、静息心电图（ECG）异常、应激期间缺血的临床或ECG体征、铊图像上可逆灌注缺损数量或随访时间（21个月）方面无统计学差异。
双嘧达莫组患者年龄稍大（64岁对57岁），且铊再分布更多（P = 0.002）。平均随访21个月后，双嘧达莫组致命和非致命（心肌梗死或心源性死亡）心脏事件更为频繁（50%对9%，P = 0.0001）。
在作者所在机构，双嘧达莫诱发TLVD的患者比运动诱发TLVD的患者风险更高。
